Tagged: , ,

Viewing 0 reply threads
  • Author
    • #21487
      John Connor

      NVG-291 may help rebuild myelin in MS patients.

      It’s currently going through the single ascending dose (SAD) part of the testing. As this has been very successful its developers are proposing it now move onto the multiple ascending dose (MAD) stage.

      Apart from the somewhat undermining medical acronyms, this looks like really promising news.

      Hope? What are your thoughts?

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account